摘要
目的探讨新型降压药乌拉地尔(URA)对高血压患者血浆降钙素基因相关肽(CGRP)和内皮素(ET)含量的影响。方法采用放射免疫方法测定15例高血压患者URA治疗前后血浆CGRP和ET含量变化。结果高血压患者血浆CGRP明显低于正常对照组(P<001)。血浆ET及ET/CGRP明显高于正常对照组(P<001)。经静脉URA治疗后5min,高血压患者血浆CGRP明显升高(P<001),ET及ET/CGRP则明显降低(P<001)。结论CGRP与ET共同在高血压发病过程中起重要作用。URA可明显提高人体内CGRP水平,在降低血压的同时对ET有明显的拮抗效应。
Objective The purpose of this paper is to determine the contents of the calcitonin gene relatecd peptide (CGRP) and endothelin (ET) in the plasma of hypertension and the effect of urapidil on the CGRP and ET. Methods RIA methods was used to measure the CGRP and ET of before and after treatment with urapidil. Results The contents of CGRP in the patients with hepertension was markedly lower than that in normal groups ( P <0 01). The content of ET in the patients with hypertension was markedly higher than that in normal patients ( P <0 01), after treatment with urapidil, the content of CGRP in plasma of patients with hypertension was significantly increased (P >0 01) and ET was significantly decreased ( P <0 01). Conclusio ns Both CGRP and ET could be an important causes of the hypertension and urapidil may markdly increasing the level of CGRP in vivo. Urapidil decreased the blood pressure and meanwhile markdly autagonistic effect to the content of ET. [
出处
《中国急救医学》
CAS
CSCD
北大核心
1999年第1期27-28,共2页
Chinese Journal of Critical Care Medicine
关键词
乌拉地尔
内皮素
高血压
CGRP
药物疗法
Urapidil Calcitonin gene related peptide Endothelin Hypertension